Do you want to read an article? Please log in or register.
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients
COPD
RECOMMENDED
Related content
COPD
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
Respir Res.
Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA
doi: 10.1186/s12931-018-0724-0.
RECOMMENDED
Further Publications
Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences
Adv Ther.
Svedsater H, Doll HA, Macey J, Miles G, Bradshaw L, Vanya M
doi: 10.1007/s12325-018-0760-7.
RECOMMENDED
COPD
Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups
Respir Med.
Bakerly ND, Woodcock A,
Collier S, Leather DA, New JP,
Crawford J, Harvey C, Vestbo J,
Boucot I
doi: 10.1016/j.rmed.2018.12.016.
RECOMMENDED
COPD
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, Wise R, Lipson DA
doi: 10.1186/s12931-020-01398-w.
Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice
N Engl J Med.
Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindale S, Collier S, Crawford J, Frith L, Harvey C, Svedsater H, Woodcock A; Salford
doi: 10.1056/NEJMoa1608033
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
Lancet.
Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE; SUMMIT Investigators
doi: 10.1016/
COPD
Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial
Ther Adv Respir Dis.
Maltais F, Schenkenberger I, Wielders PLML, Ortiz de Saracho J, Chinsky K, Watkins M, Millar V, Crim C
doi: 10.1177/1753466620965145.
RECOMMENDED
COPD
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
Adv Ther.
Naya IP, Tombs L, Lipson DA, Compton C
doi: 10.1007/s12325-018-0771-4.
Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
Read the comment: Effectiveness trials in asthma: time to SaLSA? >>>
doi: 10.1016/